<DOC>
	<DOCNO>NCT02612311</DOCNO>
	<brief_summary>This study evaluate combination ublituximab , novel monoclonal antibody , TGR-1202 , novel PI3K delta inhibitor compare obinutuzumab chlorambucil , compare ublituximab TGR-1202 alone Chronic Lymphocytic Leukemia ( CLL ) patient .</brief_summary>
	<brief_title>Ublituximab + TGR-1202 Compared Obinutuzumab + Chlorambucil Patients With Untreated Previously Treated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Treatment na√Øve previously treat Chronic Lymphocytic Leukemia ( CLL ) require treatment Eastern Cooperative Oncology Group ( ECOG ) score 0 2 Any major surgery , chemotherapy immunotherapy within last 21 day Evidence hepatitis B virus , hepatitis C virus know HIV infection Autologous hematologic stem cell transplant within 3 month study entry . Prior Allogeneic hematologic stem cell transplant exclude Transformation CLL aggressive NonHodgkin 's Lymphoma ( NHL ) ( Richter 's transformation ) Prior therapy obinutuzumab and/or chlorambucil PI3K delta inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>